May 7, 2009 Maxygen First Quarter 2009 Financial Results Conference Call Notice-Monday, May 11, 2009, 4:30 p.m. ET- REDWOOD CITY, Calif., May 7, 2009—Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, will host a conference call to discuss the company’s first quarter 2009 financial results and business updates at 4:30 p.m. ET (1:30 p.m. PT) on Monday, May 11, 2009. Russell Howard, Maxygen’s chief executive officer, will host the call. A press release announcing Maxygen’s first quarter 2009 financial results will be issued that same day at approximately 4:00 p.m. ET (1:00 p.m. PT).
Participants in the U.S. can access the call by dialing 866.804.6921 and using the passcode 85132066. International participants can dial 857.350.1667 and use the same passcode. A live webcast of the conference call will be available on the Maxygen web site at www.maxygen.com/webcasts.
Telephone and webcast replays of the conference call will be available until June 12, 2009. To access the telephone replay, dial 888.286.8010 (U.S.) or 617.801.6888 (international) and use the passcode 77659401. To access the webcast archive, go to www.maxygen.com/webcasts.
About Maxygen
Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. The company’s portfolio includes MAXY-4, partnered with Astellas Pharma, Inc., under which the company and Astellas are exploring new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis, transplantation rejection and other autoimmune disorders. Maxygen also has a MAXY-G34 program, designed to be an improved long-acting G-CSF for the treatment of neutropenia. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. www.maxygen.com
###
Contact:
Dana Fruehling
dana.fruehling@maxygen.com
650.298.5486
Return to News
|
